Arialys Therapeutics

Home Pipeline Team News Careers Contact

News

« Back to News

January 15, 2026

Arialys Presents Novel Anti-NMDAR Autoantibody Assay Data at ACNP 2026 Annual Meeting

Arialys Therapeutics presented data on a novel assay for detecting anti-NMDA receptor (NMDAR) autoantibodies at the 64th American College of Neuropsychopharmacology (ACNP) Annual Meeting, held January 12–15, 2026.

The poster described a semi-quantitative ELISA designed to detect IgG, IgA, and IgM autoantibodies targeting the N-terminal domain of the GluN1 subunit of NMDARs. Findings from patient samples demonstrated detection of these autoantibodies across neuropsychiatric and neurologic disorders, supporting further research into their potential roles in disease and as therapeutic targets.

View the ACNP poster: A Novel ELISA for Detection of Anti-NMDAR Autoantibodies

Sign up for news updates

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Follow us

©2026 Arialys Therapeutics, 11099 North Torrey Pines Rd., Ste 290, La Jolla, CA 92037